Prostate-specific membrane antigen-expressing hepatic lesion: Metastatic or hepatocellular carcinoma

“…[ 68 Ga]Ga-PSMA-11 was recently introduced for the PET/CT imaging of patients with prostate cancer, but incidental uptake has been described in other cancers, including reports on HCC [12][13][14][15][16][17][18].…”

Section: Discussionmentioning

confidence: 99%

“…Since PSMA expression is associated with poor prognosis, the results of [ 68 Ga]Ga-PSMA PET/CT have strong clinical implications [11]. However, to date, the use of [ 68 Ga]Ga-PSMA PET/CT (mainly PSMA-11) for the diagnosis of HCC has only been reported in two studies [12,13] and several case reports [14][15][16][17][18]. Therefore, this study aimed to evaluate the feasibility of PET/CT imaging with [ 68 Ga]Ga-PSMA-11 in HCC and its impact on patient management.…”

Section: Introductionmentioning

confidence: 99%

[68 Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma

Kunikowska

Cieślak

Gierej

et al. 2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Prostate-specific membrane antigen (PSMA) is not only highly expressed on the surface prostate cancer cells but is also elevated during angiogenesis in other cancer cell types, including hepatocellular carcinoma (HCC). This study aimed to evaluate the feasibility of using PET/CT imaging with [ 68 Ga]Ga-PSMA-11 in HCC and its impact on patient management. Methods Fifteen patients (13 men and two women; aged 55.6 ± 18.2 years) with HCC were enrolled in this prospective, singleinstitution study. All patients underwent contrast-enhanced MRI/CT, [ 68 Ga]Ga-PSMA-11 PET/CT, and histopathological verification of lesions. Results No radiopharmaceutical-related adverse events were noted. Visual interpretation showed increased accumulation of [ 68 Ga]Ga-PSMA-11 in all HCC patients. The tumor-to-liver ratio (TLR) was 3.6 ± 2.1, and the maximal standardized uptake value (SUV max) was 13.5 ± 7.1. There were no significant differences in the SUVs or TLR between newly diagnosed and recurrent patients. No statistically significant relationship was found between serum concentration of tumor markers (i.e., AFP, CA 19-9, CEA) and PET parameters. Results of the [ 68 Ga]Ga-PSMA-11 PET/CT changed the treatment strategy in five (33%) patients. PSMA staining showed visible heterogeneity in terms of intensity and distribution: the reaction was weak and only observed in a few vessels in pseudoglandular patterns of HCC, while it was homogeneously strong, with some hot spots, in trabecular patterns of HCC. Conclusion [ 68 Ga]Ga-PSMA-11 PET/CT can detect PSMA expression in vivo in patients with HCC and is useful for guiding treatment strategies. Further investigation of the clinical utility of this method in HCC is warranted.

show abstract

“…The majority of HCC shows high levels of PSMA expression on tumor vessels and on canalicular membrane of cells [26,28] and therefore important implications for PSMAtargeted imaging and therapy arise. PSMA-targeted imaging of HCC in clinical practice has been evaluated only by a few studies and most of these studies are case reports [22,23,[27][28][29][30][31][32][33][34], probably because of the small number of centers that currently use radiolabelled PSMA PET/CT or PET/ MRI, resulting in a reduction of the population of patients overall studied.…”

Section: Discussionmentioning

confidence: 99%

“…A total of 55 articles were extrapolated with the computer literature search and by reviewing the titles and abstracts 43 of them were excluded because the reported data were not within the field of interest of this review. Twelve articles were selected and retrieved in full-text version [22][23][24][25][26][27][28][29][30][31][32][33]; one additional study was found screening the references of these articles [34]. A total of 13 articles were then included in the systematic review [22][23][24][25][26][27][28][29][30][31][32][33][34] (Fig.…”

Section: Literature Searchmentioning

confidence: 99%

Radiolabelled PSMA PET/CT or PET/MRI in hepatocellular carcinoma (HCC): a systematic review

Dondi

Albano

Cerudelli

et al. 2020

Clin Transl Imaging

View full text Add to dashboard Cite

Introduction Radiolabelled prostate-specific membrane antigen PSMA-based PET/CT or PET/MRI is a whole-body imaging technique usually performed for the detection of prostate cancer lesions. PSMA has been also demonstrated to be expressed by the neovasculature of many other solid tumors. The aim of this review is to evaluate the possible diagnostic role of radiolabelled PSMA PET/CT or PET/MRI in patients with hepatocellular carcinoma, by summarizing the available literature data. Methods A wide literature search of the PubMed/MEDLINE, Scopus, Embase and Cochrane library databases was made to find relevant published articles about the diagnostic performance of radiolabelled PSMA binding agents in PET/CT or PET/MRI imaging of patients with hepatocellular carcinoma. Results Ten case reports and three studies showed that hepatocellular carcinoma is PSMA-avid. Conclusion Radiolabelled PSMA imaging seems to be useful in analyzing hepatocellular carcinoma. Further studies enrolling a wider population are needed to clarify the real clinical and diagnostic role of radiolabelled PSMA in this setting.

show abstract

Prostate-specific membrane antigen-expressing hepatic lesion: Metastatic or hepatocellular carcinoma

Cited by 5 publications

References 11 publications

The utility of radiolabeled PSMA ligands for tumor imaging

The utility of radiolabeled PSMA ligands for tumor imaging

[68 Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma

Radiolabelled PSMA PET/CT or PET/MRI in hepatocellular carcinoma (HCC): a systematic review

Contact Info

Product

Resources

About